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Objective.The aim of this study was to document the survival advantage of lowering stage at detection from Stage IIIC to Stage
IIIA epithelial ovarian cancer.Methods. Treatment outcomes and survival were evaluated in patients with Stage IIIA and Stage IIIC
epithelial ovarian cancer treated from 2000 to 2009 at the University of Kentucky Markey Cancer Center (UKMCC) and SEER
institutions. Results. Cytoreduction to no visible disease (𝑃 < 0.0001) and complete response to platinum-based chemotherapy
(𝑃 < 0.025) occurred more frequently in Stage IIIA than in Stage IIIC cases. Time to progression was shorter in patients with
Stage IIIC ovarian cancer (17 ± 1 months) than in those with Stage II1A disease (36 ± 8 months). Five-year overall survival (OS)
improved from 41% in Stage IIIC patients to 60% in Stage IIIA patients treated at UKMCC and from 37% to 56% in patients treated
at SEER institutions for a survival advantage of 19% in both data sets. 53% of Stage IIIA and 14% of Stage IIIC patients had NED at
last followup. Conclusions.Decreasing stage at detection from Stage IIIC to stage IIIA epithelial ovarian cancer is associated with a
5-year survival advantage of nearly 20% in patients treated by surgical tumor cytoreduction and platinum-based chemotherapy.
1. Introduction
Despite advances in radical surgery, postoperative care, and
chemotherapy, ovarian cancer remains the leading cause of
gynecologic cancer mortality among women in the United
States. This year, over 14,000 deaths from ovarian cancer
will be reported in the United States alone [1]. Most women
continue to present with advanced disease where the cost of
treatment is high and survival is low. Since the 5-year survival
of patients with early stage ovarian cancer is excellent, many
investigators believe that the most effective way to reduce
ovarian cancer mortality is through earlier detection. It has
been estimated that if 75% of ovarian cancer cases were
detectedwith early stage disease, the number of women dying
of this cancer could be reduced by one half. Recent data from
3 of the 4 major ovarian cancer screening trials indicates that
regular screening of high risk populationswith a combination
of serum [2–5] biomarkers and ultrasound is associated with
a decrease in stage at detection. Specifically, a statistically
higher percent of ovarian cancer patients detected through
screening had Stage I or II disease when compared to ovarian
cancer patients in control populations detected clinically [2–
4] in the United Kingdom Collaborative Trial of Ovarian
Cancer Screening (UKCTOCS), the Multicenter Japanese
Trial, and theUniversity of KentuckyOvarianCancer Screen-
ing (UKOCS) trial. In addition, a substage shift from Stage
IIIC to Stage IIIA in cases detected by screening was reported
in one of these trials [4]. The following investigation was
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undertaken to document the survival advantage associated
with reducing substage at detection from Stage IIIC to Stage
IIIA epithelial ovarian cancer in the era of primary tumor
cytoreduction followed by platinum-based chemotherapy.
2. Methods
This investigation was undertaken after approval of the
University of Kentucky Human Subjects Institutional Review
Board. All patients with FIGO Stage IIIA and Stage IIIC
epithelial ovarian cancer treated from 2000 to 2009 were
identified from the UKMCC Tumor Registry and the SEER
18 Cancer Registry. Data abstracted from both registries
included stage and substage at detection, cell type of epithelial
ovarian cancer, age at diagnosis, number of live births at
diagnosis, race, and geographic location (Appalachian versus
non-Appalachian), and being urban versus being rural. In
addition, hospital and outpatient records were reviewed on
all patients treated at the UKMCC in order to determine
the extent of surgical tumor cytoreduction, response to
chemotherapy, time to disease progression, and sites of
recurrence. Patients treated at the UKMCC all underwent
standard surgical staging including total abdominal hys-
terectomy, bilateral salpingo-oophorectomy, omentectomy,
and pelvic/paraaortic lymph node sampling. Bowel resection,
splenectomy, and other upper abdominal surgeries were
performed on a case by case basis, in an attempt to achieve
maximal tumor cytoreduction. Complete debulking was
defined as no visible residual tumor after surgical cytore-
duction. Tumors were classified histologically according to
the World Health Organization system and were staged
according to the International Federation of Gynecology
and Obstetrics (FIGO) Staging System (Table 1) [6]. Fol-
lowing surgery, patients were entered on Institutional or
Gynecologic Oncology Group (GOG) Treatment Protocols,
which usually included a minimum of 6 cycles of platinum-
based chemotherapy. Patients were examined clinically at
monthly intervals during chemotherapy, every 3 months for
the next 2 years, and every 6 months thereafter. Ca 125
biomarker determinations were obtained at the time of clin-
ical examination, and CT scans of the chest, abdomen, and
pelvis were performed when indicated at 6-month intervals.
Selected patients with an abnormality onCT scan or doubling
serum biomarker levels underwent PET scans and CT-
directed needle biopsies to confirm the presence of recurrent
disease.
Criteria for tumor response and progression were those
recommended by the Response Evaluation Criteria in Solid
Tumors (RECIST) Committee [7, 8]. Complete response
(CR) was defined as normal clinical biomarker levels and
no clinical or radiographic evidence of disease, and partial
response (PR) was defined as at least a 30% decrease in the
sum of the longest measurable tumor diameter as measured
by CT scan,MRI, or X-ray. Tumor progression was defined as
at least a 20% increase in the sum of the longest measurable
tumor diameter, or greater than a doubling of serum Ca-
125 in the presence of radiographically identifiable disease
[8]. Time to progression was defined as the time from pri-
mary diagnosis to documented disease progression. Platinum
sensitivity was determined 6 months from completion of
chemotherapy. Patients classified as platinum-sensitive had a
CR or PR to primary platinum therapy and no evidence of
progression within 6 months of completing chemotherapy.
Platinum-resistant patients had less than a PR to primary
platinum therapy or had a CR or PR and experienced tumor
progression less than 6 months after completing chemother-
apy. Platinum-sensitive patients experiencing tumor recur-
rence were treated again with platinum-based chemotherapy,
whereas platinum-resistant patients were treated with single
agent chemotherapy on an individual basis. Patient follow-
up was coordinated by the UKMCC Institutional Cancer
Registry, the American Cancer Society, and the Kentucky
StateDepartment of Vital Statistics. Overall survival (OS)was
defined as the time from primary diagnosis to death from
any cause. Survivors were censored on the last date they were
known to be alive.
3. Statistical Analysis
All analyses were conducted using SAS software version 9.2
(SAS Institute Inc., Cary, NC, USA, 2008); tests were two-
sided and 𝑃 values ≤0.05 were considered statistically signifi-
cant.The chi-square test was used to compare categorical data
and the independent samples 𝑡-test for comparing continuous
data between subgroups. Time-to-event data were analyzed
using the Kaplan-Meier method and the log-rank test was
used to compare survival distributions between groups.
4. Results
From 2000 to 2009, 15 patients with Stage IIIA and 186
patients with Stage IIIC epithelial ovarian cancer were treated
at the UKMCC. Five of the patients with Stage IIIA ovarian
cancer and 7 of the patients with Stage IIIC ovarian cancer
were detected by screening. Demographic data for patients
treated at the UKMCC from 2000 to 2009 are presented
in Table 2. There were no significant differences in age at
detection, race, geographic location, or ovarian cancer cell
type in patients with Stage IIIA disease versus those with
Stage IIIC disease. During this time period, 794 patients
with Stage IIIA and 11,967 patients with Stage IIIC ovarian
cancer were treated at 18 institutions in the SEER database
(Table 3). There were no significant demographic differences
in between patients with Stage IIIA and Stage IIIC ovarian
cancer treated at SEER institutions. However, there was a
slightly higher frequency of endometrioid and mucinous
cell types in patients with Stage IIIA disease and a slightly
higher frequency of serous cell types in those with Stage IIIC
disease.
Outcomes of patients with Stages IIIA and IIIC ovarian
cancer treated at the UKMCC from 2000 to 2009 are
presented in Table 4. Surgical cytoreduction to no visible
disease was achieved in 100% of Stage IIIA patients and in
34.4% of Stage IIIC patients (𝑃 < 0.0001). Sixty-five per-
cent of patients with Stage IIIC ovarian cancer had <1 cm
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Table 1: Definitions of Stage IIIA and Stage IIIC ovarian cancer∗.
Stage III
Tumor involves one or both ovaries with cytologically or histologically confirmed spread to the peritoneum outside the pelvis
and/or metastasis to the retroperitoneal lymph nodes.
Stage IIIA
Microscopic metastasis beyond the pelvis.
Stage IIIC
Macroscopic, extrapelvic, peritoneal metastasis >2 cm in the greatest dimension and/or regional lymph node metastasis.
∗From Edge et al. [6].
Table 2: Demographic data Stage IIIA versus Stage IIIC epithelial ovarian cancer, University of KentuckyMarkey Cancer Center 2000–2009.
IIIA IIIC Significance
Mean Mean
Age at diagnosis 58.6 ± 15.9 58.2 ± 12.4 𝑃 = 0.89
Number of live births at diagnosis 1.9 ± 2.1 2.1 ± 1.6 𝑃 = 0.54
𝑁 𝑁
Race
Black 0 1 (0.5%)
White 15 (100%) 185 (99.5%) 𝑃 = 0.78
Other 0 0
Appalachian Region
Appalachia 8 (53%) 115 (62%) 𝑃 = 0.52
Non-Appalachia 7 (47%) 71 (38%)
Urban region
Rural 5 (33%) 70 (38%) 𝑃 = 0.74
Urban 10 (67%) 116 (62%)
Cell type
Serous carcinoma 8 (54%) 118 (63%)
Endometrioid carcinoma 3 (20%) 17 (10%) 𝑃 = 0.46
Mixed adenocarcinoma (NOS) 2 (13%) 36 (19%)
Clear cell, mucinous, carcinoma (NOS) 2 (13%) 15 (8%)
NOS: not otherwise specified.
residual disease after tumor debulking. All patients with
Stage IIIA ovarian cancer experienced a complete response
(CR) to platinum-based chemotherapy (as defined by no
radiologic or biomarker evidence of disease after 6 cycles
of chemotherapy) versus 74.2% of patients with Stage IIIC
disease (𝑃 < 0.025). As expected, the most common sites of
recurrence in both stage groups were intraperitoneal, but 12%
of Stage IIIC cases also developed extraperitoneal spread.The
most common sites of extraperitoneal recurrence were lung
(10), liver (6), brain (2), and inguinal lymph nodes (2). The
mean time to progressionwas significantly shorter (𝑃 < 0.01)
in patients with Stage IIIC disease (17 ± 1.3 months) than in
patients with Stage IIIA disease (36 ± 8 months).
The overall survival (OS) of patients with Stages IIIA and
IIIC epithelial ovarian cancer treated at the UKMCC and the
SEER institutions is presented in Figure 1. The 5-year OS of
patients with Stage IIIA disease treated at the UKMCC was
60% compared to 41% in patients with Stage IIIC disease
(Figure 1(a)). Moreover, 53% of patients with Stage IIIA
ovarian cancer had no evidence of disease at the time of their
last follow-up visit versus 14.5% of patients with Stage IIIC
ovarian cancer (𝑃 < 0.0008). The 5-year OS of Stage IIIA
ovarian cancer patients treated at SEER institutions was 56%
compared to 37% in Stage IIIC cases (Figure 1(b)). Therefore,
the 5-year survival advantage associated with downstaging
IIIC to IIIA ovarian cancer was 19% both in patients treated
at the UKMCC and in those treated at the SEER institutions.
The small number of patients with Stage IIIA ovarian cancer
treated at the UKMCC (𝑁 = 15) limited meaningful survival
analysis. However, the same 19% survival advantage observed
between Stage IIIA cases and Stage IIIC cases treated at SEER
institutions was highly significant (𝑃 < 0.0001) when a
greater number of patients were included in both Stage III
subgroups.
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Table 3: Demographic data Stage IIIA versus Stage IIIC epithelial ovarian cancer, US SEER 18 Registries 2000–2009.
Stage IIIA IIIC Significance
Number 794 11,967
Age at diagnosis (mean) 63.2 ± 14.4 62.2 ± 14.8 𝑃 = 0.42
𝑁 𝑁
Race
Black 49 (6.2%) 712 (5.9%)
𝑃 = 0.18White 680 (85.6%) 10,456 (87.4%)
Other 65 (8.2%) 799 (6.7%)
Appalachian Region
Appalachia 30 (3.8%) 539 (4.5%)
𝑃 = 0.34
Non-Appalachia 764 (96.2%) 11,428 (95.5%)
Urban region
Rural 78 (9.8%) 1,199 (10.0%)
𝑃 = 0.86
Urban 716 (90.2%) 10,768 (90.0%)
Cell type
Serous carcinoma 396 (50.0%) 7,952 (66.4%)
𝑃 = 0.05
Endometrioid carcinoma 90 (11.3%) 740 (6.2%)
Mixed adenocarcinoma (NOS) 32 (4.0%) 437 (3.7%)
Mucinous carcinoma 91 (11.5%) 1,282 (10.7%)
Carcinoma (NOS), other 185 (23.2%) 1,556 (13.0%)
NOS: not otherwise specified.
Table 4: Treatment outcomes Stage IIIA versus Stage IIIC epithelial ovarian cancer, University of Kentucky Markey Cancer Center 2000–
2009.
IIIA IIIC Significance
(𝑁 = 15) (𝑁 = 186)
Complete debulking
(no visible residual disease) 15 (100%) 64 (34.4%) 𝑃 < 0.0001
Complete response to chemotherapy 15 (100%) 138 (74.2%) 𝑃 = 0.025
Time to progression
Median (months) 29 13
Mean (months)∗ 36 ± 8 17 ± 1.3 𝑃 < 0.01
Range (months) 15–75 2–123
Site of recurrence
Intraperitoneal 7 (46.7%) 137 (73.7%)
Intra- + extraperitoneal 0 8 (4.3%)
Extraperitoneal 0 14 (7.5%)
NED∗∗ 8 (53.3%) 27 (14.5%) 𝑃 < 0.008
Overall survival
2 years 93.3% 72.0% 𝑃 < 0.07
5 years 60.0% 41.8%
∗Mean ± standard error of mean.
∗∗NED: no evidence of disease.
The 5-year OS of UKMCC patients with completely
debulked Stage IIIC ovarian cancer was 64.8%.This is similar
to the OS of UKMCC patients with Stage IIIA ovarian cancer
and significantly higher (𝑃 < 0.0001) than the 29.7% survival
of UKMCC patients with incompletely debulked Stage IIIC
disease.
5. Discussion
Sonographic and biomarker screening of asymptomatic
women at high risk for ovarian cancer has been initiated in
several countries as a means to lower stage at diagnosis [2–5].
Also, tumor morphology indexing and serum biomarker
Journal of Oncology 5
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Figure 1: (a) Overall survival of Stage IIIA versus Stage IIIC epithelial ovarian cancer patients at the University of Kentucky Markey Cancer
Center (2000–2009). (b) Overall survival of Stage IIIA versus Stage IIIC epithelial ovarian cancer patients in SEER∗18 Registries (2000–2009).
profiling have been used to identify ovarian tumors at the
highest risk of malignancy so that women with these tumors
can be referred to tertiary care centers for their surgery [9–
13].The goal of these efforts is to promote earlier detection of
ovarian cancer and to enable patients with thesemalignancies
to be treated earlier in the disease process by gynecologic
oncologists. The rationale of these approaches is based on
the reported excellent 5-year survival rate of patients with
early stage ovarian cancers and the improved outcomes of
those receiving appropriate surgery and chemotherapy [14].
Although the effect of screening on ovarian cancer mortal-
ity has not yet been answered definitively, the efficacy of
screening tests to detect early stage disease in asymptomatic
women is well documented. For example, the UKCTOCS [2]
screened 202,638 postmenopausal women and reported that
47% of ovarian cancer patients detected by screening had
Stage I or II disease versus 26% in the unscreened control
population (𝑃 < 0.005) [2]. Similarly, 63% of ovarian cancer
patients detected by screening in the Multicenter Japanese
Trial had Stage I disease versus 38% in the control group [3].
In a recent report from the ongoingUKOCS trial, not only
were 68% of ovarian cancer patients diagnosed with Stage
I or II disease, but there was also a decrease in substage at
detection in patients with Stage III disease [4]. Specifically, of
the 14 screen-detected patients with Stage III ovarian cancer,
5 patients (36%) had Stage IIIA disease, and 3 patients (21%)
had Stage IIIB disease. As a result, the 5-year survival of Stage
III cases detected by screening was significantly higher than
that of clinically detected Stage III cases, 84% of whom had
Stage IIIC disease.
Findings of the present investigation confirm a significant
outcomes benefit to patients when stage at detection is
reduced from Stage IIIC to IIIA. In patients with Stage IIIA
disease, there was a statistically significant increase in the
frequency of successful tumor debulking, complete response
to platinum-based chemotherapy, and disease-free status.
As a result, there was a significant survival advantage of
almost 20% in patients with Stage IIIA ovarian cancer when
compared to those with Stage IIIC disease in both the SEER
and UKMCC groups. Since one-third of the patients with
Stage IIIA ovarian cancer in theUKMCC series were detected
by screening, lead time bias may have contributed to the
observed increase in survival noted. However, this bias would
not be apparent in the SEER cases since all patients were
detected clinically. Also, there may be a biologic difference
in ovarian cancer according to substage in patients treated
at SEER institutions since there was a higher frequency
of endometrioid cancer in Stage IIIA cases and a higher
frequency of serous cancers in those with Stage IIIC disease.
The prognostic effect of complete tumor debulking was
noted in this study and confirmed the findings of several prior
investigations [15–18]. The 5-year OS of completely debulked
UKMCC Stage IIIC cases was 64.8% as compared to 29.7%
in patients with visible residual disease after cytoreductive
surgery. Interestingly, the 5-year OS of completely debulked
Stage IIIC cases was approximately the same as the 60% OS
of Stage IIIA cases observed in this study. This is consistent
with the observations of Le et al. [19], who reported that 81
completely cytoreduced patients with Stage IIIB-IIIC ovarian
cancer had essentially the same survival as 24 Stage IIA-IIIA
completely cytoreduced patients with no visible extrapelvic
disease. Similarly, Eisenkop et al. [17], in a study of 408
patients with Stage IIIC ovarian cancer, concluded that the
completeness of surgical cytoreduction had amore significant
effect on prognosis than the extent of metastatic disease
prior to surgery. Our observations, however, are somewhat
at variance with those of Hoskins et al. [20]. These authors
stratified 349 patients with Stage III ovarian cancer, all of
whom were cytoreduced to ≤1 cm residual disease, according
to extent of disease prior to surgery. Patients with >1 cm
extrapelvic disease before surgery had amedian survival of 31
months, whereas those with ≤1 cm extrapelvic disease before
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surgery had a median survival of 51 months. These authors
concluded that the innate biological properties of ovarian
cancer play a more important role in determining prognosis
than the extent of surgical cytoreduction.
Although the present investigation is retrospective, it
does provide a detailed comparison of patients with Stages
IIIA and IIIC epithelial ovarian cancer, all of whom received
complete surgical staging, tumor debulking, and platinum-
based chemotherapy during the same time period by gyne-
cologic oncologists at one institution.The number of patients
with clinically detected Stage IIIA ovarian cancer remains
small, thereby prolonging the time requirement necessary to
complete a prospective comparison of patients within Stage
III. In the present study, however, analysis of data from SEER
institutions allowed outcomes of a large number of patients
with Stage IIIA ovarian cancer to be compared to those of
an even greater number of patients with Stage IIIC disease.
Importantly, the improvement in survival from Stage IIIC
to Stage IIIA was identical in both data sets and was highly
significant in the SEER experience.
The findings of this investigation confirm a significant
survival benefit of earlier detection in epithelial ovarian
cancer, not only by increasing the frequency of patients with
early stage disease, but also by diagnosing Stage III cancers
at an earlier substage. The 19% 5-year survival advantage
observed in patients with Stage IIIA versus Stage IIIC ovarian
cancer is significant and should encourage further research
into methods to improve the earlier detection of this disease.
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